ShangPharma mulling private equity takeover

CRO ShangPharma is considering an offer from private equity firm TPG Star Charisma to buy up the Chinese company's outstanding shares. ShangPharma has brought in JP Morgan for consulting, and the company is valued at up to $176 million, according to Outsourcing-Pharma. Among the CRO's clients are Eli Lilly ($LLY) and GlaxoSmithKline ($GSK). Report

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.